2025 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
China’s biopharma sector is pushing forward with significant innovations, particularly in oncology and biologics, though market pressures and regulatory hurdles continue to pose challenges for sustained growth.
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Quietly but unambiguously, pharma firms are accelerating their diversification away from China and are now looking to other emerging markets for growth, a strategy that reflects increasing pressures from China's volume-based procurement scheme but also US-China tensions and other geopolitical risks.
The latest FDA guidance will have profound impact to Chinese biotech sector at a time when going global and a US approval is vital to its very survival.
